Search
Find a recruiting study
7,120 recruiting studies with US sites, from the official ClinicalTrials.gov registry (refreshed Oct 26, 2026). No sign-up needed.
Most recently updated studies · page 65 of 297
- RecruitingPhase 2
A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss)
Eli Lilly and Company
- Location
- Fremont, CA + 8 other US sites
- Eligibility basics
- Ages 18–60
- RecruitingPhase 3
A Study to Evaluate the Pharmacokinetics and Safety of XEMBIFY Versus Gamunex-C in Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Grifols Therapeutics LLC
- Location
- Rancho Mirage, CA + 7 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
Study of YOLT-203 in Children and Adults With Primary Hyperoxaluria Type 1 (PH1)
YolTech Therapeutics Co., Ltd
- Location
- Birmingham, AL + 1 other US site
- Eligibility basics
- Ages 6+
- RecruitingPhase 2
Study Evaluating the Efficacy, Safety, and Tolerability of ASY202 (Dihydroergotamine Mesylate [DHE] Inhalation Powder Delivered Via a Multidose Dry Powder Inhaler) for the Acute Treatment of Migraine in Adult Patients
Aspeya, Inc.
- Location
- Phoenix, AZ + 19 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 2
A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Study Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD) With Chronic Bronchitis
UCB Biopharma SRL
- Location
- Miami, FL + 6 other US sites
- Eligibility basics
- Ages 40–80
- RecruitingPhase 2
Study of EO2002 in Subjects With Corneal Edema Secondary to Corneal Endothelial Dysfunction
Emmecell
- Location
- Carmel, IN
- Eligibility basics
- Ages 21+
- RecruitingPhase 3
A Study of Secutrelvir in Participants With Coronavirus Disease 2019 (COVID-19) Who Are at High Risk for Progression to Severe Disease
Shionogi
- Location
- Cincinnati, OH
- Eligibility basics
- Ages 12+
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of Subcutaneous Nomlabofusp in Subjects With Friedreich's Ataxia
Larimar Therapeutics, Inc.
- Location
- Chicago, IL + 2 other US sites
- Eligibility basics
- Ages 12–40
- RecruitingPhase 3
A Study to Assess the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
GlaxoSmithKline
- Location
- Sherman Oaks, CA + 2 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine (NAL) Extended-Release (ER) Tablets
Trevi Therapeutics
- Location
- Wilmington, DE + 3 other US sites
- Eligibility basics
- Ages 40+
- RecruitingPhase 3
A Study to Learn About the Study Medicine Called Tilrekimig ( PF-07275315) in People With Severe Asthma
Pfizer
- Location
- Pittsburgh, PA + 1 other US site
- Eligibility basics
- Ages 12–80
- Recruiting
Retraining Neural Pathways Improves Cognitive Skills After A Mild Traumatic Brain Injury
Perception Dynamics Institute
- Location
- San Diego, CA + 1 other US site
- Eligibility basics
- Ages 18–60
- Recruiting
A Study to Evaluate the Safety and Effectiveness of the InnAVasc Arteriovenous Graft for Hemodialysis Access in Patients With End-Stage Renal Disease
W.L.Gore & Associates
- Location
- Phoenix, AZ + 20 other US sites
- Eligibility basics
- Ages 18–90
- RecruitingPhase 2
A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition
Regeneron Pharmaceuticals
- Location
- Peoria, AZ + 34 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures
Xenon Pharmaceuticals Inc.
- Location
- Phoenix, AZ + 44 other US sites
- Eligibility basics
- Ages 12+
- RecruitingPhase 3
A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)
Xenon Pharmaceuticals Inc.
- Location
- Los Angeles, CA + 14 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 1/Phase 2
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Persons With Severe or Moderate Hemophilia A
Hoffmann-La Roche
- Location
- Sacramento, CA + 2 other US sites
- Eligibility basics
- Ages 2–59 · Men only
- RecruitingPhase 2
Dexmedetomidine Transdermal Systems (DMTS) Treatment for Agitation Associated With Dementia of the Alzheimer's Type
Teikoku Pharma USA, Inc.
- Location
- Chino, CA + 7 other US sites
- Eligibility basics
- Any age listed
- RecruitingPhase 2
Efficacy and Safety Study of OATD-01 in Patients With Active Pulmonary Sarcoidosis
Molecure S.A.
- Location
- Baltimore, MD + 3 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)
- Location
- Lancaster, CA + 22 other US sites
- Eligibility basics
- Ages 18–85
- RecruitingPhase 3
Pegtibatinase as a Treatment for Participants With Classical Homocystinuria (HCU) Receiving Standard of Care Treatment
Travere Therapeutics, Inc.
- Location
- Phoenix, AZ + 11 other US sites
- Eligibility basics
- Ages 12–65
- RecruitingPhase 1/Phase 2
ATTUNE: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intrathecally-Administered ION440 in Participants With Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome (MDS)
Ionis Pharmaceuticals, Inc.
- Location
- San Diego, CA + 7 other US sites
- Eligibility basics
- Ages 2–65 · Men only
- Recruiting
The PERSEVERE Study
Inari Medical
- Location
- New Haven, CT + 15 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis
CSL Behring
- Location
- Oakland, CA + 18 other US sites
- Eligibility basics
- Ages 12+
Data source: deploy-time snapshot of the ClinicalTrials.gov API. How we list studies